Achelois Oncology

Achelois Oncology is a UK-based biotechnology company focused on developing next-generation cancer therapeutics by targeting the E2F transcription factor pathway. Spun out from the University of Oxford, the company leverages the research of Professor Nick La Thangue to create small molecule inhibitors that disrupt the cell cycle in malignant cells. The E2F pathway is a central regulator of cell proliferation and is commonly overactive in many types of cancer, making it a high-value target for precision medicine. Achelois is currently advancing its lead programs through pre-clinical development, aiming to address unmet needs in solid tumor treatment. The company is backed by prominent life science investors, including Oxford Science Enterprises.